title: Marked shrinkage of amyloid lymphadenopathy after an intensive chemotherapy in a patient with IgM-associated AL amyloidosis.
abstract: A male patient with primary AL amyloidosis who had been suffering from systemic lymphadenopathy with IgMkappa-type M-proteinemia received two courses of VAD and high-dose melphalan with in vivo elimination of CD20(+) cells using rituximab followed by autologous peripheral blood stem cell transplantation. Four years after complete hematological remission he showed marked reduction in size of the amyloid-laden lymph nodes. Deposits of AL amyloid may regress from the tissue if the chemotherapy succeeds in persistent inhibition of the production of an amyloidogenic immunoglobulin light chain.
authors.forename: Ko-Ichi
authors.initials: K
authors.lastname: Tazawa
authors.forename: Nagaaki
authors.initials: N
authors.lastname: Katoh
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Shimojima
authors.forename: Masayuki
authors.initials: M
authors.lastname: Matsuda
authors.forename: Shu-Ichi
authors.initials: S
authors.lastname: Ikeda
mesh_terms: D000682:Amyloid / Q000378:metabolism*; D000686:Amyloidosis / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology*; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D006801:Humans; D008206:Lymphatic Diseases / Q000188:drug therapy / Q000209:etiology / Q000473:pathology; D008297:Male; D008558:Melphalan / Q000627:therapeutic use*; D008875:Middle Aged
chemical_list: D000682:Amyloid; D018906:Antineoplastic Agents, Alkylating; D008558:Melphalan